Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 23, Issue 8, Pages 1031-1043
Publisher
Elsevier BV
Online
2022-07-08
DOI
10.1016/s1470-2045(22)00293-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Revisiting Richter transformation in the era of novel CLL agents
- (2021) Anna Petrackova et al. BLOOD REVIEWS
- Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
- (2021) Amy S. Ruppert et al. LEUKEMIA
- A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy
- (2021) Yun Choi et al. BLOOD
- Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study
- (2020) John C. Byrd et al. CLINICAL CANCER RESEARCH
- Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
- (2020) Yuqin Song et al. CLINICAL CANCER RESEARCH
- Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
- (2020) Wei Xu et al. Journal of Hematology & Oncology
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY
- (2020) Constantine S. Tam et al. BLOOD
- Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
- (2020) Inhye E. Ahn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2020) B. Eichhorst et al. ANNALS OF ONCOLOGY
- Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion
- (2020) Constantine S. Tam et al. HAEMATOLOGICA
- Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
- (2019) Constantine Si Lun Tam et al. BLOOD
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2019) Yunhang Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- (2018) Michael Hallek et al. BLOOD
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
- (2017) Tjeerd Barf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients
- (2016) B. D. Hock et al. INTERNAL MEDICINE JOURNAL
- Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL
- (2016) C Maurer et al. LEUKEMIA
- Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States
- (2015) Mintu P. Turakhia et al. AMERICAN JOURNAL OF CARDIOLOGY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
- (2012) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- A Manual of Guidelines to Score the Modified Cumulative Illness Rating Scale and Its Validation in Acute Hospitalized Elderly Patients
- (2008) Fabio Salvi et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started